In a study known as CROWNS-2 published in JAMA, the researchers randomly assigned 180 adults with CRSwNP to stapokibart (300 ...

Celldex will stop development of barzolvolimab in eosinophilic esophagitis, but it will continue progressing the drug in ...

With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the market will grow ...

Anabelle Terry, a slender, self-possessed 13-year-old, has heard the peanut butter story her entire life. A visit to an ...

For severe chronic rhinosinusitis with nasal polyps, novel stapokibart reduced symptoms and polyp size atop treatment with a ...

The ongoing study could significantly impact the stock performance of Regeneron and Sanofi, as successful results may enhance their market position and investor confidence. The development of ...

Manufacturing Regeneron says Novo plant problems caused another CRL and will delay 2 Eylea decisions By Kevin Dunleavy Aug 1, 2025 11:51am Regeneron Pharmaceuticals Eylea drug manufacturing Novo ...

Regeneron outlines path to $17B Dupixent annual sales and initiates 10 Lynozyfic registrational trials amid robust Q2 growth ...

Nektar Therapeutics is fairly valued based on rNPV modeling, but multiple near-term catalysts could drive upside. Learn why ...

Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company reported strong second-quarter financial results that significantly surpassed analyst ...

The FDA, which last year rejected Regeneron's initial odronextamab application due to issues related to the enrollment status of confirmatory trials, accepted the company's resubmitted application ...

Regeneron Q2 revenue rose 4% to $3.68 billion, driven by Dupixent and antibody profits, while FDA delays impacted Eylea HD and odronextamab approvals.